Affymetrix Sued by Investment Fund Over Pending eBioscience Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix is being sued by Tang Capital Partners over the Santa Clara, Calif.-based firm's proposed purchase of eBioscience.

In a document filed with the US Securities and Exchange Commission today, Affy said that the class action lawsuit, filed with the Superior Court of California, County of Santa Clara, alleges the purchase would constitute a fundamental change under the indenture that governs 3.50 percent senior convertible notes due 2038 held by Tang Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.